Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
ClinicoEconomics and Outcomes Research · 2026-05 · Volume 18 · 1-13
DOI: 10.2147/ceor.s585328 ↗Kurz gefasst
Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-05. Verfasst von Enrico Torre und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetology and Metabolic Diseases Unit, ASL3 Genoa, Genoa, Italy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetology and Metabolic Diseases Unit, ASL3 Genoa, Genoa, Italy.
- Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy.
- Department of Drug Sciences, University of Pavia, Pavia, Italy.
- Internal Medicine Unit, ASL3 Genoa, Genoa, Italy.
- Otolaryngology Unit, ASL3 Genoa, Genoa, Italy.
- General Direction, ASL3 Genoa, Genoa, Italy.
ORCID-Profile: Enrico Torre, Chiara Martinotti, Giacomo Matteo Bruno, Giorgio Lorenzo Colombo
Zitieren
APA
Torre, E., Di Matteo, S., Martinotti, C., Bruno, G. M., Cabrino, A., Fogliati, E. L., Giusti, A., Barbieri, M., Bottaro, L. C., & Colombo, G. L. (2026). Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective. ClinicoEconomics and Outcomes Research, Volume 18, 1-13. https://doi.org/10.2147/ceor.s585328
Vancouver
Torre E, Di Matteo S, Martinotti C, Bruno GM, Cabrino A, Fogliati EL, et al. Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-13. doi:10.2147/ceor.s585328
BibTeX
@article{Torre2026,
author = {Torre, Enrico and Di Matteo, Sergio and Martinotti, Chiara and Bruno, Giacomo Matteo and Cabrino, Alessandro and Fogliati, Emma Lucia and Giusti, Andrea and Barbieri, Marco and Bottaro, Luigi Carlo and Colombo, Giorgio Lorenzo},
title = {Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective},
journal = {ClinicoEconomics and Outcomes Research},
year = {2026},
volume = {Volume 18},
pages = {1--13},
doi = {10.2147/ceor.s585328}
}
EUVIMED